NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that on October 1, 2026, it received a letter (the "Staff Determination") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities ("MVLS") of $35 million for continued listing on The Nasdaq Capital Market (the "MVLS Requirement"). The Company intends to appeal the Staff Determination by timely requesting a hearing before the Nasdaq Hearings Panel and seeking additional time to regain compliance with the MVLS Requirement.